Evidence map›Paper›PMID 39449805›Full record

ArticleOncology research2024

Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation

Jinxia Chen, Suli Dai, Geng Zhang, Sisi Wei, Xuetao Zhao, Yang Zheng, Yaojie Wang, Xiaohan Wang, Yunjiang Liu, Lianmei Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jinxia ChenResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Suli DaiResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Geng ZhangBreast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Sisi WeiResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Xuetao ZhaoDepartment of Blood Transfusion, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Yang ZhengResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Yaojie WangResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Xiaohan WangResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Yunjiang LiuBreast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Lianmei ZhaoResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triple-negative breast cancer (TNBC) is a heterogeneous, recurring cancer characterized by a high rate of metastasis, poor prognosis, and lack of efficient therapies. KBU2046, a small molecule inhibitor, can inhibit cell motility in malignant tumors, including breast cancer. However, the specific targets and the corresponding mechanism of its function remain unclear. Methods: In this study, we employed (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay and transwell assay to investigate the impact of KBU2046 on the proliferation and migration of TNBC cells Results: In this study, we found that KBU2046 functioned as a novel transforming growth factor-β (TGF-β1) inhibitor, effectively suppressing tumor cell motility Conclusions: In summary, these findings advocate for the utilization of TGF-β1 as a diagnostic and prognostic biomarker and as a therapeutic target in TNBC. Furthermore, our data underscore the potential of KBU2046 as a novel therapeutic strategy for combating cancer metastasis.

Indexed as

Cell MovementCell ProliferationTransforming Growth Factor beta1Triple Negative Breast NeoplasmsAntineoplastic AgentsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansSignal TransductionAntineoplastic AgentsTGFB1 protein, humanTransforming Growth Factor beta1Breast cancer (BC)Integrin α6Integrin αvKBU2046LRRC (leucine-rich repeat-containing)LTBP (leucine-rich repeat-containing)TGF-β1 (transforming growth factor-β1)

Identifiers

PMID39449805
PMCPMC11497199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.